**Press Release**

# Alembic Pharmaceuticals reports resilient Q1 FY27 performance

## Revenue up 26%; EBITDA up 21% YoY

**Vadodara, August 4th, 2026:** Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June 2026.

**Financial Highlights for Q1 FY27**

- Revenue from operations increased by 26% YoY to Rs.2150 Cr.
- Profit After Tax at Rs. 173 Cr, up 12% YoY
- EBITDA pre R&D increased to Rs. 523 Cr; margin stood at 24%

**Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said,**

"We have started FY27 on a strong note, delivering broad-based growth across our businesses. Performance during the quarter was driven by healthy volume growth, successful new product launches and continued execution across key markets. The US business delivered strong momentum, and the rest of the markets also recorded steady growth. We remain focused on strengthening our product portfolio, advancing our pipeline and driving sustainable long-term growth."

**Operational Highlights**

**India Branded Business**

- India Branded Business delivered 7% YoY growth, reaching Rs 642 Cr. in revenue for the quarter.
- Gynaecology, Gastrology and Ophthalmology have shown robust growth.
- Animal healthcare segment delivered encouraging performance during the quarter.
- 3 new products were introduced during the quarter.

**International Business**

- US Formulation grew by 49% to Rs. 778 Cr.
- 7 Launches in the US market during the quarter.
- Ex-US Generics grew by 17% to Rs. 383 Cr.
- 10 ANDA approvals received during the quarter

**API Business**

- API business grew by 33% to Rs. 346 Cr.

The summary of Revenue from Operations is as under:

(Rs in Cr.)

| Particulars | Q1 FY26 | Q1 FY27 | % Change |
|---|---|---|---|
| **Formulation** | | | |
| India | 599 | 642 | 7% |
| USA | 523 | 778 | 49% |
| Ex- US | 328 | 383 | 17% |
| **API** | 261 | 346 | 33% |
| **Total** | **1711** | **2150** | **26%** |

**Earnings Call:** Alembic Pharmaceuticals Limited will host an investor call at 5.30 pm IST on August 04, 2026, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1411/ +91 22 7115 8312. Other toll numbers are listed in the conference call invitation, which is posted on the Company website www.alembicpharmaceuticals.com. The operator will provide instructions on asking questions before the start of the call.

**About Alembic Pharmaceuticals Limited**

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India.

Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

**For more information, contact:**

**Isha Lamba: Phone: +91 022- 66951652 Email: isha.lamba@alembic.co.in**